原标题:6至8个药物将进入临床,诺诚健华研发支出接近翻番 来源:北京日报客户端在接下来的18个月,诺诚健华将有6至8个候选药物进入临床,从而使其进入临床阶段的药物将增加到10多个。3月26日,北京生物医药高科技公司诺诚健华发布的2020年全年业绩报告和公司进展还显示,其研发支出已由2019年的2.131亿元增加到2020年的4.028亿元。“我们于2020年3月23日在港交所上市,成为2020年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.